Neutrophils mediate Th17 promotion in COVID-19 patients.
COVID-19
G-MDSC
IL-17
SARS-CoV-2
Th17
immature neutrophils
neutrophils
Journal
Journal of leukocyte biology
ISSN: 1938-3673
Titre abrégé: J Leukoc Biol
Pays: England
ID NLM: 8405628
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
03
08
2020
revised:
04
11
2020
accepted:
07
11
2020
pubmed:
9
12
2020
medline:
2
3
2021
entrez:
8
12
2020
Statut:
ppublish
Résumé
From the beginning of 2020, an urgent need to understand the pathophysiology of SARS-CoV-2 disease (COVID-19), much of which is due to dysbalanced immune responses, resonates across the world. COVID-19-associated neutrophilia, increased neutrophil-to-lymphocyte ratio, aberrant neutrophil activation, and infiltration of neutrophils into lungs suggest that neutrophils are important players in the disease immunopathology. The main objective of this study was to assess the phenotypic and functional characteristics of neutrophils in COVID-19 patients, with particular focus on the interaction between neutrophils and T cells. We hypothesize that the altered functional characteristics of COVID-19 patient-derived neutrophils result in skewed Th1/Th17 adaptive immune response, thus contributing to disease pathology. The expansion of G-MDSC and immature forms of neutrophils was shown in the COVID-19 patients. In the COVID-19 neutrophil/T cell cocultures, neutrophils caused a strong polarity shift toward Th17, and, conversely, a reduction of IFNγ-producing Th1 cells. The Th17 promotion was NOS dependent. Neutrophils, the known modulators of adaptive immunity, skew the polarization of T cells toward the Th17 promotion and Th1 suppression in COVID-19 patients, contributing to the discoordinated orchestration of immune response against SARS-CoV-2. As IL-17 and other Th17-related cytokines have previously been shown to correlate with the disease severity, we suggest that targeting neutrophils and/or Th17 represents a potentially beneficial therapeutic strategy for severe COVID-19 patients.
Identifiants
pubmed: 33289169
doi: 10.1002/JLB.4COVCRA0820-481RRR
pmc: PMC7753339
doi:
Substances chimiques
Interleukin-17
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
73-76Subventions
Organisme : Czech Ministry of Health AZV
ID : NU20-05-00320
Organisme : Czech Ministry of Health AZV
ID : GAUK 954218
Informations de copyright
©2020 Society for Leukocyte Biology.
Références
Nat Rev Immunol. 2020 Jun;20(6):345-346
pubmed: 32358580
Immunity. 2019 Oct 15;51(4):671-681.e5
pubmed: 31451397
J Immunol. 2012 Aug 15;189(4):1639-47
pubmed: 22798682
Cytokine. 2018 Apr;104:8-13
pubmed: 29414327
Sci Transl Med. 2016 Mar 23;8(331):331ra40
pubmed: 27009269
J Exp Med. 2013 Jul 1;210(7):1433-445
pubmed: 23797095
J Transl Med. 2020 May 20;18(1):206
pubmed: 32434518
Nat Rev Immunol. 2020 May;20(5):269-270
pubmed: 32273594
Immunology. 2020 Jul;160(3):261-268
pubmed: 32460357
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Br J Pharmacol. 2009 Oct;158(3):638-51
pubmed: 19764983
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Blood. 2020 Sep 3;136(10):1169-1179
pubmed: 32597954
Blood. 2010 Jan 14;115(2):335-43
pubmed: 19890092
Cells. 2020 Sep 29;9(10):
pubmed: 33003471